We aimed to investigate the different outcomes in patients with metastatic renal cell carcinoma treated with secondline axitinib or everolimus after sunitinib. Patients treated in 16 oncological centres in Italy were included, and those receiving axitinib or everolimus from January 2013 onwards were analysed for outcomes. Descriptive statistical tests were used to highlight differences between groups. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Data on 634 patients with metastatic renal cell carcinoma treated with first-line sunitinib have been obtained. A total of 182 patients received a second-line therapy with everolimus (79 patients, 43%) or axitinib (103 patients, 57%), respectively. The median PFS was 4.6 [95% confidence (CI): 2.6-6.5] months for patients treated with everolimus and 5.5 (95% CI: 4.3-6.7) months for patients treated with axitinib (P = 0.7). The median OS was 13.9 (95% CI: 10.4-17.4) months for patients treated with everolimus and 12.0 (95% CI: 7.9-16.2) months for patients treated with axitinib (P = 0.3). No differences were found based on length of firstline treatment. Major limitations are the retrospective nature of the study and the lack of a prospective evaluation of the progression. This study reports no significantly differences between everolimus and axitinib in terms of both PFS and OS. Furthermore, the length of first-line treatment cannot be used as such a predictive factor and cannot suggest the use of a molecule compared with another.
Introduction
In recent years, several agents targeting the vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGFR) pathway and the mammalian target of rapamycin axis have been approved for the treatment of metastatic renal cell carcinoma (mRCC) based on advantages in clinical outcomes [mainly progression-free survival (PFS)] demonstrated in large phase III clinical trials. Until recently, everolimus and axitinib have long been considered to be standard second-line options after progression to a VEGFR inhibitor. The RECORD-1 trial comparing everolimus with a placebo in patients previously treated with one or two VEGFR tyrosine kinase inhibitors (TKIs) reported a significantly longer PFS in patients who received everolimus. In contrast, the AXIS trial comparing axitinib with sorafenib in patients previously treated mainly (but not exclusively) with sunitinib reported a longer PFS in those who received axitinib. Despite this, neither study was able to demonstrate a significant improvement in overall survival (OS) owing to many reasons, such as the cross-over permitted in the RECORD-1 trial or (possibly) the subsequent therapies received in the AXIS trial [1, 2] .
Recently, new evidence on immunotherapy and new generations of TKIs has increased the available options after the failure of first-line treatment with a VEGFR TKI in mRCC [3] . As a result, the heterogeneity and complexity of the sequence of therapy has increased and old questions remain unanswered. Everolimus and axitinib have never been directly compared in a prospective trial; therefore, the treatment choice is based mainly on the physician's expertise, supported by indirect -and ultimately inconclusive -comparison, than on sound evidence-based data [4] . Furthermore, in countries such as Italy, the use of axitinib is limited for patients whose disease has progressed during/after sunitinib treatment, whereas everolimus is available for those who experienced progression after treatment with different VEGFR TKIs.
Despite the fact that only about half of patients treated with first-line targeted agents are eligible for new therapy, the treatment choice is an important issue in clinical practice because of the following: (i) there is a possibility of improving PFS, OS and disease-related symptoms; (ii) some patients receive second-line therapy owing to firstline treatment-related adverse event which led to its discontinuation; (iii) the number of patients receiving multiple lines of treatment is increasing and (iv) patients and their families ask for further therapy.
In this study, we aim to report the clinical outcomes in a large cohort of patients treated with second-line everolimus or axitinib after progression with sunitinib.
Patients and methods

Patients
Given the 2013 approval of axitinib by the Italian National Drug Agency (AIFA) limited to patients previously treated with sunitinib, this retrospective analysis was restricted to patients treated with first-line sunitinib and receiving second-line therapy from 2013 onwards. Patients from 16 oncological centres with a histological diagnosis of clear-cell renal cell carcinoma and treated with first-line sunitinib at the standard dose followed by second-line axitinib or everolimus were included in the study.
Adequate information about the baseline Eastern Cooperative Oncology Group Performance Status, the extent of the disease and the biochemical parameters was also required. The prognostic group at baseline was evaluated for each patient using the International mRCC Database Consortium criteria [5] .
The patients were divided into two groups based on whether they had received sunitinib followed by axitinib or everolimus; baseline characteristics and outcomes were analysed separately.
Statistics
Baseline values were expressed as the median value. The baseline was defined as the start date of second-line treatment with everolimus or axitinib. The PFS was evaluated from the start of therapy with everolimus or axitinib to the disease progression or death. Patients were assessed for progression every 12 weeks by the RECIST criteria (version 1.0) according to the AIFA guidelines. OS was evaluated from the start of treatment with axitinib or everolimus to death or last follow-up. All survivals were estimated by the Kaplan-Meier method and compared across groups using the log-rank test. A χ 2 -test or t-test was used to compare groups when appropriate. All the variables were considered to be significant if P-value is less than 0.05. The PASW software (Predictive Analytics Software, IBM Corp., Released 2012. IBM SPSS Statistics for Windows, Version 21.0, IBM Corp., Armonk, New York, USA) was used for the analysis. The approval of the ethics committee was obtained for this study.
Results
Patients
Data regarding 634 patients treated with first-line sunitinib were obtained. Among these, only 393 (61.9%) received second-line therapy, and only 182 patients who had been treated with second-line axitinib or everolimus since January 2013 were included in the analysis.
A total of 175 of 182 patients showed progression under sunitinib, and the median PFS was 12.6 months.
A total of 79 (43%) patients received everolimus and 103 (57%) axitinib. No significant differences among baseline characteristics before the second-line treatment were found between the two groups, except for the rate of patients with metastatic disease at diagnosis (31.6 vs. 47.6; P = 0.03) and the rate of male patients (62.0 vs. 80.6%; P = 0.005) ( Table 1) .
Second-line outcome
After a median follow-up period of 50.2 months since the start of first-line treatment, 154 (86.6%) patients progressed to second-line treatment, and 104 (57.1%) patients died. The median OS from the start of sunitinib was 34.9 [95% confidence interval (CI): 28.7-41.2] months.
The median PFS was 4.6 (95% CI: 2.6-6.5) months for patients treated with everolimus and 5.5 (95% CI: 4.3-6.7) months for patients treated with axitinib; no significant differences were found (P = 0.7) (Fig. 1) . The median PFS was longer in patient treated with axitinib and showed good prognosis (17.0 vs. 5.4 months; P = 0.031), whereas no differences were found in patients with intermediate (5.5 vs. 3.5 months; P = 0.8), or poor (2.6 vs. 3.8 months; P = 0.2) prognostic class. No differences between everolimus and axitinib were also found in patients with PFS to sunitinib greater (4.9 vs. 6.0; P = 0.5) or below (3.1 vs. 4.0; P = 0.5) to the median value.
The median OS was 13.9 (95% CI: 10.4-17.4) months for patients treated with everolimus and 12.0 (95% CI: 7.9-16.2) months for patients treated with axitinib; no significant differences were found (P = 0.3) (Fig. 2) . The median OS was longer in patient treated with everolimus and showed poor prognosis (9.9 vs. 3.2 months; P = 0.002), whereas no differences were found in patients with good (29.3 vs. 22.7 months; P = 0.5), or intermediate (12.8 vs. 12.0 months; P = 0.9), prognostic class. No differences between everolimus and axitinib were also found in patients with PFS to sunitinib greater (29.3 vs. 17.0; P = 0.5) or below (11.6 vs. 7.9; P = 0.3) to the median value.
The median total OS from the start of sunitinib was 33.0 months for patients who received everolimus and 37.2 months in those treated with second-line axitinib; no significant differences were found (P = 0.4).
Subsequent lines
A total of 87 (48%) patients received further lines of therapy, and outcomes were comparable in those who received second-line everolimus (49%) and axitinib (47%). The residual survival from the end of second-line treatment to death or the last follow-up in patients who progressed to axitinib or everolimus was 11.4 months in those who received third-line therapy compared with less than 1 month in those who did not (P < 0.001). Kaplan-Meier curves for progression-free survival in patients treated with everolimus or axitinib. Kaplan-Meier curves for overall survival in patients treated with everolimus or axitinib.
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Discussion
To the best of our knowledge, this is the largest study that investigated the difference between everolimus and axitinib after sunitinib in mRCC. The study reports no significant differences between the two treatments in terms of both PFS and OS. The sequence of therapy is an important clinical issue for physicians involved in the treatment of mRCC, owing to the disparity between the number of available options and the lack of comparative trials [6] . In this context, everolimus has long been the gold standard of care for second-line therapy in patients with mRCC based on the positive results of the RECORD-1 trial and the favourable toxicity profile compared with those of the anti-VEGFR TKIs, as confirmed by the RECORD-3 trial [7, 8] .
In terms of efficacy, our study reports a median value of 33.0 months for the total OS in patients treated with sunitinib and everolimus, which is comparable to the 29.5 months reported in the prospective RECORD-3 trial as well as the median PFS for everolimus was comparable to reported values in other prospective clinical trials [7] [8] [9] .
In contrast, the sequence of sunitinib followed by axitinib has been investigated in the AXIS prospective phase III trial [10] . The reported median PFS value of 4.8 months in patients treated with axitinib is comparable to the 5.5 months identified in our analysis. Unfortunately, there is only a retrospective study recently published in the medical literature about the sequence of sunitinib and axitinib. This study reports no statistically significant differences between axitinib and everolimus in terms of both OS and PFS [11] .
Comparisons between second-line treatment with anti-VEGFR TKIs or mammalian targets of rapamycin after first-line sunitinib have previously been investigated in a large phase III trial, where sorafenib was compared with temsirolimus. That study did not report any differences in terms of PFS, but OS significantly improved in patients treated with second-line sorafenib (16.6 vs. 12.3 months, P = 0.01) [12] . Evidence from that trial has not translated into clinical practice owing to differences between sorafenib and axitinib and between temsirolimus and everolimus [1, 13] . As everolimus has long been considered the gold standard in second-line treatment in mRCC treatment, it has been used as control arm in two recent phase III trials [14, 15] . In those studies, a comparison has been made between everolimus and the monoclonal antibody against the PD1 nivolumab and the novel multikinase inhibitor cabozantinib, with significant improvements in OS reported for the new treatments. Consequently, the use of everolimus in second-line therapy is not recommended when nivolumab and cabozantinib are available [16, 17] , and not prospective evidences comparing axitinib with everolimus, nivolumab or cabozantinib are available. Despite this, new therapies are inaccessible in some parts of the world owing to their cost or delays in negotiating reimbursement levels by local regulatory authorities. Moreover, new data on axitinib and everolimus and their comparisons, even if retrospective, may provide support to clinicians in areas of the world where new option are not available, whereas everolimus and axitinib do.
This study also confirms the prognostic role of the length of first-line treatment reporting longer survival in second-line treatment in patients with good outcome to the first one. Unfortunately, this cannot be used as a predictive factor because of the similar outcome for everolimus and axitinib both in patients with a first-line PFS above or below the median value. On the basis of these data, we confirm that the length of first-line treatment should be considered when evaluating prognoses in second-line therapy, as recently suggested in a revision of a large monocentric experience [18] , but not for the choice between everolimus and axitinib.
This study has some limitations, mainly owing to its retrospective nature data on patient comorbidities, toxicity management and concomitant treatments were unavailable. Lastly, even though the AIFA guidelines dictate the timing of disease assessments in patients treated with highcost drugs in Italy, doubts about the consistency of these assessments across different centres remain. Nevertheless, the strength of our study is its provision of data from a large cohort of real-world patients where survival outcomes are comparable to available prospective trials. Moreover, we tried to reduce the risk of bias related to the selection by including only those patients treated in a period of time when axitinib and everolimus were both commercially available.
Finally, this study reports no significantly differences between everolimus and axitinib in terms of both PFS and OS. Furthermore, the length of first-line cannot be used such as a predictive factor and cannot suggest the use of a molecule compared with another. These data might serve as a background in an evolving scenario where new options are coming and old ones were shifted for subsequent line or for personalized approach.
